Yersal Ozlem, Barutca Sabri
Ozlem Yersal, Sabri Barutca, Division of Medical Oncology, Department of Internal Medicine, Medical Faculty, Adnan Menderes University, 09010 Aydin, Turkey.
World J Clin Oncol. 2014 Aug 10;5(3):412-24. doi: 10.5306/wjco.v5.i3.412.
Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with distinct biological features that lead to differences in response patterns to various treatment modalities and clinical outcomes. Traditional classification systems regarding biological characteristics may have limitations for patient-tailored treatment strategies. Tumors with similar clinical and pathological presentations may have different behaviors. Analyses of breast cancer with new molecular techniques now hold promise for the development of more accurate tests for the prediction of recurrence. Gene signatures have been developed as predictors of response to therapy and protein gene products that have direct roles in driving the biology and clinical behavior of cancer cells are potential targets for the development of novel therapeutics. The present review summarizes current knowledge in breast cancer molecular biology, focusing on novel prognostic and predictive factors.
乳腺癌是一种异质性复杂疾病,是多种具有不同生物学特征的亚型的集合,这些特征导致对各种治疗方式的反应模式和临床结果存在差异。关于生物学特征的传统分类系统在制定针对患者的治疗策略方面可能存在局限性。具有相似临床和病理表现的肿瘤可能具有不同的行为。现在,利用新的分子技术对乳腺癌进行分析有望开发出更准确的复发预测检测方法。基因特征已被开发用作治疗反应的预测指标,而在驱动癌细胞生物学和临床行为中起直接作用的蛋白质基因产物是新型治疗药物开发的潜在靶点。本综述总结了乳腺癌分子生物学的当前知识,重点关注新的预后和预测因素。